{"product_id":"cjc-1295-ipamorelin","title":"CJC-1295 + Ipamorelin","description":"\u003cblockquote\u003e\n\u003cdiv data-framer-component-type=\"RichTextContainer\" data-framer-name=\"Strong → Research Use Only.\" class=\"framer-17icvk9\"\u003e\u003cem\u003e\u003cstrong\u003eResearch Use Only\u003c\/strong\u003e\u003c\/em\u003e\u003c\/div\u003e\n\u003cdiv data-framer-component-type=\"RichTextContainer\" data-framer-name=\"Strong → Research Use Only.\" class=\"framer-1j4pnbk\"\u003eAll products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.\u003cbr\u003e\u003cbr\u003e\n\u003cdiv data-framer-component-type=\"RichTextContainer\" data-framer-name=\"Overview Header\" class=\"framer-e299os\"\u003e\n\u003ch2 dir=\"auto\" data-styles-preset=\"Ze7_hb2TJ\" class=\"framer-text framer-styles-preset-17n1ut5\"\u003eCJC-1295 + Ipamorelin Overview\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv data-framer-component-type=\"RichTextContainer\" data-framer-name=\"Overview Body\" class=\"framer-8mbkxy\"\u003eThe CJC-1295 + Ipamorelin blend combines two peptides studied for their effects on endocrine signaling pathways. CJC-1295, a GHRH analog, is associated with sustained modulation of somatotroph axis activity and downstream signaling cascades. Ipamorelin, a selective secretagogue-type peptide, has been studied for its selective pituitary signaling activity without significant off-target pathway interference. Together, they may provide complementary activity across multiple endocrine and systemic pathways in experimental settings.\n\u003ch2 class=\"framer-text framer-styles-preset-2if8ww\" dir=\"auto\"\u003e\n\u003ca rel=\"noopener\" href=\"https:\/\/academic.oup.com\/jcem\/article\/91\/3\/799\/2843281\" class=\"framer-text framer-styles-preset-dxoa8s\" target=\"_blank\"\u003eTeichman S.L. et al. (2006).\u003c\/a\u003e\u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eHistory\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cdiv data-framer-component-type=\"RichTextContainer\" data-framer-name=\"History Body\" class=\"framer-1e0s2rr\"\u003eThe concept of the CJC-1295 + Ipamorelin blend stems from parallel developments in peptide research aimed at exploring growth hormone modulation. CJC-1295, a synthetic analog of growth hormone–releasing hormone (GHRH), was developed in the early 2000s to extend the half-life and activity of natural GHRH fragments for research into growth hormone and IGF-1 pathways. Meanwhile, Ipamorelin—a selective ghrelin receptor agonist—emerged from studies in the 1990s investigating ghrelin mimetics and their ability to stimulate growth hormone release with minimal off-target hormonal effects. Together, these peptides became of interest for laboratory research into growth hormone regulation, recovery, and metabolic processes.\u003ca rel=\"noopener\" href=\"https:\/\/academic.oup.com\/jcem\/article\/83\/9\/3094\/2865290\" class=\"framer-text framer-styles-preset-dxoa8s\" target=\"_blank\"\u003eSvensson J. et al. (1998).\u003c\/a\u003e\n\u003c\/div\u003e\n\u003cdiv data-framer-name=\"Structure Section 1\" data-border=\"true\" class=\"framer-rpntv3\"\u003e\n\u003cdiv data-framer-name=\"Content\" class=\"framer-dg5g2i\"\u003e\n\u003ch2 dir=\"auto\" data-styles-preset=\"Ze7_hb2TJ\" class=\"framer-text framer-styles-preset-17n1ut5\"\u003eCJC-1295 Structure\u003c\/h2\u003e\n\u003cbr\u003e\n\u003cdiv data-framer-name=\"Structure Image\" class=\"framer-hfrwpj\"\u003e\n\u003cimg alt=\"\" src=\"https:\/\/framerusercontent.com\/images\/xZj1CALgrW6R9UnD9374DGOaU.svg?width=980\u0026amp;height=126\" srcset=\"https:\/\/framerusercontent.com\/images\/xZj1CALgrW6R9UnD9374DGOaU.svg?scale-down-to=512\u0026amp;width=980\u0026amp;height=126 512w,https:\/\/framerusercontent.com\/images\/xZj1CALgrW6R9UnD9374DGOaU.svg?width=980\u0026amp;height=126 980w\" sizes=\"calc(max((min(100vw, 980px) - 82px) \/ 1.95, 1px) - 48px)\" height=\"126\" width=\"980\" loading=\"lazy\" decoding=\"auto\"\u003e\n\u003cdiv data-framer-background-image-wrapper=\"true\"\u003e\n\u003cem\u003e\u003cstrong\u003eMolecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂\u003c\/strong\u003e\u003c\/em\u003e\u003cem\u003e\u003cstrong\u003eMolecular Weight: 3367.9 g\/mol\u003c\/strong\u003e\u003c\/em\u003e\n\u003cdiv data-framer-component-type=\"RichTextContainer\" data-framer-name=\"PubChem ID\" class=\"framer-5d66tv\"\u003e\n\u003cem\u003e\u003cstrong\u003ePubChem ID: 91976842\u003cbr\u003e\u003cbr\u003e\u003c\/strong\u003e\u003c\/em\u003e\n\u003cdiv data-framer-component-type=\"RichTextContainer\" data-framer-name=\"Resarch Findings Header\" class=\"framer-138hud5\"\u003e\n\u003ch2 dir=\"auto\" data-styles-preset=\"Ze7_hb2TJ\" class=\"framer-text framer-styles-preset-17n1ut5\"\u003eResearch Findings\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv data-framer-component-type=\"RichTextContainer\" data-framer-name=\"Research Findings Body\" class=\"framer-1pwxkmo\"\u003eCJC-1295 and Ipamorelin have been examined in endocrine, signaling, experimental, and systemic models, with research exploring their influence on somatotroph axis pathways, downstream cascades, pathway activity, and molecular viability. Studies highlight their role in signaling kinetics, remodeling processes, and systemic resilience in preclinical settings.\u003cstrong class=\"framer-text\"\u003eKey Areas of Research:\u003c\/strong\u003e\n\u003cul class=\"framer-text\" dir=\"auto\"\u003e\n\u003cli class=\"framer-text framer-styles-preset-2if8ww\" data-preset-tag=\"p\"\u003eEndocrine: Somatotroph axis, signaling, cascades\u003c\/li\u003e\n\u003cli class=\"framer-text framer-styles-preset-2if8ww\" data-preset-tag=\"p\"\u003eSignaling: Lipid pathways, dynamics, markers\u003c\/li\u003e\n\u003cli class=\"framer-text framer-styles-preset-2if8ww\" data-preset-tag=\"p\"\u003eMolecular: Proliferation, remodeling, viability\u003c\/li\u003e\n\u003cli class=\"framer-text framer-styles-preset-2if8ww\" data-preset-tag=\"p\"\u003eSystemic: Vascular, resilience, pathway activity\u003c\/li\u003e\n\u003c\/ul\u003e\nTogether, these findings suggest broad experimental potential for CJC-1295 and Ipamorelin across multiple biological pathways. By modulating endocrine signaling, influencing downstream pathway activity, and supporting molecular and systemic resilience, this combination provides a versatile platform for research into remodeling, pathway dynamics, and experimental modeling in laboratory settings.\u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.1210\/jc.2005-2175\" class=\"framer-text framer-styles-preset-dxoa8s\"\u003eTeichman S.L. et al., Journal of Clinical Endocrinology \u0026amp; Metabolism, 2006\u003c\/a\u003e\n\u003c\/div\u003e\n\u003cdiv data-framer-name=\"References\" data-border=\"true\" class=\"framer-14l2n57\"\u003e\n\u003cdiv data-framer-name=\"Content\" class=\"framer-15p1962\"\u003e\n\u003cdiv data-framer-component-type=\"RichTextContainer\" data-framer-name=\"Research Use Only\" class=\"framer-1ecatqh\"\u003e\n\u003ch2 dir=\"auto\" data-styles-preset=\"Ze7_hb2TJ\" class=\"framer-text framer-styles-preset-17n1ut5\"\u003eReferences\u003cbr\u003e\n\u003c\/h2\u003e\n\u003ca rel=\"noopener\" href=\"https:\/\/academic.oup.com\/jcem\/article\/91\/3\/799\/2843281\" class=\"framer-text framer-styles-preset-dxoa8s\" target=\"_blank\"\u003eTeichman S.L. et al. (2006). \u003cem class=\"framer-text\"\u003eProlonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults.\u003c\/em\u003e J Clin Endocrinol Metab, 91(3):799-805. \u003c\/a\u003e\u003ca rel=\"noopener\" href=\"https:\/\/journals.physiology.org\/doi\/pdf\/10.1152\/ajpendo.00201.2006\" class=\"framer-text framer-styles-preset-dxoa8s\" target=\"_blank\"\u003eLapierre S.S. et al. (2006). \u003cem class=\"framer-text\"\u003eSustained GH and IGF-1 responses to CJC-1295 in GHRH knockout mice.\u003c\/em\u003e Am J Physiol Endocrinol Metab, 291(2):E282-E287.\u003c\/a\u003e\u003ca rel=\"noopener\" href=\"https:\/\/academic.oup.com\/jcem\/article\/83\/9\/3094\/2865290\" class=\"framer-text framer-styles-preset-dxoa8s\" target=\"_blank\"\u003eSvensson J. et al. (1998). \u003cem class=\"framer-text\"\u003eIpamorelin selectively stimulates GH release without affecting cortisol or prolactin.\u003c\/em\u003e J Clin Endocrinol Metab, 83(9):3094-3101.\u003c\/a\u003e\u003ca rel=\"noopener\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12176660\" class=\"framer-text framer-styles-preset-dxoa8s\" target=\"_blank\"\u003eCuller M.D. et al. (2002). \u003cem class=\"framer-text\"\u003ePharmacological characterization of ipamorelin, a novel GHRP with GH selectivity.\u003c\/em\u003e J Endocrinol, 174(2):R1-R6.\u003c\/a\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/blockquote\u003e","brand":"Peptiders","offers":[{"title":"Single Vial","offer_id":44963872669782,"sku":null,"price":89.0,"currency_code":"USD","in_stock":true},{"title":"Pack of 10","offer_id":44963872702550,"sku":null,"price":799.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/8787\/7206\/files\/GW2WlUrSDyiS6qKou8Rc6LVlA.avif?v=1781633454","url":"https:\/\/peptidersresearch.com\/products\/cjc-1295-ipamorelin","provider":"Peptiders Researcher","version":"1.0","type":"link"}